Literature DB >> 25265230

Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries.

.   

Abstract

BACKGROUND: There is little information on the incidence of AIDS-defining events which have been reported in the literature to be associated with immune reconstitution inflammatory syndrome (IRIS) after combined antiretroviral therapy (cART) initiation. These events include tuberculosis, mycobacterium avium complex (MAC), cytomegalovirus (CMV) retinitis, progressive multifocal leukoencephalopathy (PML), herpes simplex virus (HSV), Kaposi sarcoma, non-Hodgkin lymphoma (NHL), cryptococcosis and candidiasis.
METHODS: We identified individuals in the HIV-CAUSAL Collaboration, which includes data from six European countries and the US, who were HIV-positive between 1996 and 2013, antiretroviral therapy naive, aged at least 18 years, had CD4 cell count and HIV-RNA measurements and had been AIDS-free for at least 1 month between those measurements and the start of follow-up. For each AIDS-defining event, we estimated the hazard ratio for no cART versus less than 3 and at least 3 months since cART initiation, adjusting for time-varying CD4 cell count and HIV-RNA via inverse probability weighting.
RESULTS: Out of 96 562 eligible individuals (78% men) with median (interquantile range) follow-up of 31 [13,65] months, 55 144 initiated cART. The number of cases varied between 898 for tuberculosis and 113 for PML. Compared with non-cART initiation, the hazard ratio (95% confidence intervals) up to 3 months after cART initiation were 1.21 (0.90-1.63) for tuberculosis, 2.61 (1.05-6.49) for MAC, 1.17 (0.34-4.08) for CMV retinitis, 1.18 (0.62-2.26) for PML, 1.21 (0.83-1.75) for HSV, 1.18 (0.87-1.58) for Kaposi sarcoma, 1.56 (0.82-2.95) for NHL, 1.11 (0.56-2.18) for cryptococcosis and 0.77 (0.40-1.49) for candidiasis.
CONCLUSION: With the potential exception of mycobacterial infections, unmasking IRIS does not appear to be a common complication of cART initiation in high-income countries. 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25265230      PMCID: PMC4495885          DOI: 10.1097/QAD.0000000000000456

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  31 in total

Review 1.  Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy.

Authors:  Samuel A Shelburne; Richard J Hamill; Maria C Rodriguez-Barradas; Stephen B Greenberg; Robert L Atmar; Daniel W Musher; Joseph C Gathe; Fehmida Visnegarwala; Barbara W Trautner
Journal:  Medicine (Baltimore)       Date:  2002-05       Impact factor: 1.889

Review 2.  Immune restoration disease after antiretroviral therapy.

Authors:  Martyn A French; Patricia Price; Shelley F Stone
Journal:  AIDS       Date:  2004-08-20       Impact factor: 4.177

Review 3.  Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: emergence of a new syndrome of immune reconstitution and changing patterns of disease.

Authors:  Leonard H Calabrese; Elizabeth Kirchner; Rabin Shrestha
Journal:  Semin Arthritis Rheum       Date:  2005-12       Impact factor: 5.532

4.  Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS.

Authors:  M Narita; D Ashkin; E S Hollender; A E Pitchenik
Journal:  Am J Respir Crit Care Med       Date:  1998-07       Impact factor: 21.405

5.  Lymphoma immune reconstitution inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohort.

Authors:  Satish Gopal; Monita R Patel; Chad J Achenbach; Elizabeth L Yanik; Stephen R Cole; Sonia Napravnik; Greer A Burkholder; W Christopher Mathews; Benigno Rodriguez; Steven G Deeks; Kenneth H Mayer; Richard D Moore; Mari M Kitahata; Kristy L Richards; Joseph J Eron
Journal:  Clin Infect Dis       Date:  2014-04-21       Impact factor: 9.079

6.  Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.

Authors:  Julia del Amo; Santiago Moreno; Heiner C Bucher; Hansjakob Furrer; Roger Logan; Jonathan Sterne; Santiago Pérez-Hoyos; Inma Jarrín; Andrew Phillips; Sara Lodi; Ard van Sighem; Wolf de Wolf; Caroline Sabin; Loveleen Bansi; Amy Justice; Joseph Goulet; José M Miró; Elena Ferrer; Laurence Meyer; Rémonie Seng; Giota Toulomi; Panagiotis Gargalianos; Dominique Costagliola; Sophie Abgrall; Miguel A Hernán
Journal:  Clin Infect Dis       Date:  2012-03-28       Impact factor: 9.079

7.  AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.

Authors:  B Ledergerber; M Egger; V Erard; R Weber; B Hirschel; H Furrer; M Battegay; P Vernazza; E Bernasconi; M Opravil; D Kaufmann; P Sudre; P Francioli; A Telenti
Journal:  JAMA       Date:  1999-12-15       Impact factor: 56.272

8.  Zidovudine-induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients.

Authors:  M A French; S A Mallal; R L Dawkins
Journal:  AIDS       Date:  1992-11       Impact factor: 4.177

Review 9.  CNS-immune reconstitution inflammatory syndrome in the setting of HIV infection, part 1: overview and discussion of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome and cryptococcal-immune reconstitution inflammatory syndrome.

Authors:  M J D Post; M M Thurnher; D B Clifford; A Nath; R G Gonzalez; R K Gupta; K K Post
Journal:  AJNR Am J Neuroradiol       Date:  2012-07-12       Impact factor: 3.825

10.  Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options.

Authors:  David M Murdoch; Willem D F Venter; Annelies Van Rie; Charles Feldman
Journal:  AIDS Res Ther       Date:  2007-05-08       Impact factor: 2.250

View more
  8 in total

Review 1.  Neurological immune reconstitution inflammatory response: riding the tide of immune recovery.

Authors:  David B Clifford
Journal:  Curr Opin Neurol       Date:  2015-06       Impact factor: 5.710

2.  Timing of Antiretroviral Treatment, Immunovirologic Status, and TB Risk: Implications for Testing and Treatment.

Authors:  April C Pettit; Adell Mendes; Cathy Jenkins; Sonia Napravnik; Aimee Freeman; Bryan E Shepherd; David Dowdy; John Gill; Anita Rachlis; Richard Moore; Timothy R Sterling
Journal:  J Acquir Immune Defic Syndr       Date:  2016-08-15       Impact factor: 3.731

3.  Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples.

Authors:  Sara Lodi; Andrew Phillips; Jens Lundgren; Roger Logan; Shweta Sharma; Stephen R Cole; Abdel Babiker; Matthew Law; Haitao Chu; Dana Byrne; Andrzej Horban; Jonathan A C Sterne; Kholoud Porter; Caroline Sabin; Dominique Costagliola; Sophie Abgrall; John Gill; Giota Touloumi; Antonio G Pacheco; Ard van Sighem; Peter Reiss; Heiner C Bucher; Alexandra Montoliu Giménez; Inmaculada Jarrin; Linda Wittkop; Laurence Meyer; Santiago Perez-Hoyos; Amy Justice; James D Neaton; Miguel A Hernán
Journal:  Am J Epidemiol       Date:  2019-08-01       Impact factor: 5.363

4.  Short- and Long-term Risks of Highly Active Antiretroviral Treatment with Incident Opportunistic Infections among People Living with HIV/AIDS.

Authors:  Yung-Feng Yen; Marcelo Chen; I-An Jen; Pei-Hung Chuang; Chun-Yuan Lee; Su-I Lin; Yi-Ming Arthur Chen
Journal:  Sci Rep       Date:  2019-03-05       Impact factor: 4.379

5.  Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study).

Authors:  Guido Schäfer; Christian Hoffmann; Keikawus Arasteh; Dirk Schürmann; Christoph Stephan; Björn Jensen; Matthias Stoll; Johannes R Bogner; Gerd Faetkenheuer; Jürgen Rockstroh; Hartwig Klinker; Georg Härter; Albrecht Stöhr; Olaf Degen; Eric Freiwald; Anja Hüfner; Sabine Jordan; Julian Schulze Zur Wiesch; Marylyn Addo; Ansgar W Lohse; Jan van Lunzen; Stefan Schmiedel
Journal:  AIDS Res Ther       Date:  2019-11-15       Impact factor: 2.250

Review 6.  MRI imaging features of HIV-related central nervous system diseases: diagnosis by pattern recognition in daily practice.

Authors:  Mio Sakai; Masahiro Higashi; Takuya Fujiwara; Tomoko Uehira; Takuma Shirasaka; Katsuyuki Nakanishi; Nobuo Kashiwagi; Hisashi Tanaka; Hitoshi Terada; Noriyuki Tomiyama
Journal:  Jpn J Radiol       Date:  2021-06-14       Impact factor: 2.374

7.  Pleuropulmonary Kaposi Sarcoma in the Setting of Immune Reactivation.

Authors:  Karthik Suresh; Roy Semaan; Sixto Arias; Petros Karakousis; Hans Lee
Journal:  J Pulm Respir Med       Date:  2016-05-30

8.  Characteristics of Invasive Fungal Infections among HIV Individuals from an Indigenous Origin in Mexico.

Authors:  Mercedes Aranda-Audelo; Norma E Rivera-Martínez; Dora E Corzo-León
Journal:  J Fungi (Basel)       Date:  2018-09-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.